MailMyPrescriptions is a licensed and accredited US Pharmacy with the following Certifications:
Powered by GeniusRx
How does an FSA work?
Flexible Spending Accounts will reimburse you for incurred expenses during your FSA plan year (period of coverage).
“Incurred” refers to expenses that happen after a service or product is provided – not when you are billed or pay for the service.You cannot be reimbursed in advance for any services.
Because FSA funds are available to you on the first day of your plan year, you must be able to receive full reimbursement for your contribution.
So, if you opted in for $1,200 a year for your FSA, you could use that amount on the first day (if you wanted to).
You can submit for FSA reimbursement in two ways:
1. Your FSA Administrator might provide you with an FSA Debit Card to use toward FSA eligible expenses.
You’ll be able to use the card at approved stores or pharmacies (we accept FSA Debit Cards and all major credit cards at FSAstore.com!)
By using the FSA debit card, your expenses are auto-adjudicated (electronically approved or disapproved) from the card and you may not need to submit additional receipts to your FSA Administrator.
Some FSA Administrators could still require a receipt to substantiate a claim. Check with your FSA Administrator about reimbursement procedures for your plan.The FSA Debit Card would not be charged if something is not considered FSA eligible under your plan.
2. You’ll have to typically submit a reimbursement claims form with:
- your personal details,
- product/service details(provider information)
- amount owed
- date of service provided.
FSAstore.com can provide you with an itemized receipt after you make your order to submit to your FSA Administrator for FSA reimbursement.
Brinzolamide ophthalmic suspension is used topically to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension. Safety and efficacy of brinzolamide were evaluated in several randomized active- and placebo-controlled studies. In these studies, brinzolamide was as effective as dorzolamide in reducing IOP in patients with glaucoma or ocular hypertension; brinzolamide was less effective than timolol in reducing IOP. Tolerance to brinzolamide apparently does not occur; the reduction in IOP has been maintained over at least 18 months of brinzolamide therapy. When topical brinzolamide is used in conjunction with a topical β-adrenergic blocking agent (e.g., timolol), the IOP-lowering effects of these agents may be additive. In one study in patients with open-angle glaucoma or ocular hypertension in whom IOP was not adequately controlled with timolol alone, addition of brinzolamide to timolol therapy resulted in further decreases in IOP.
Dosage and Administration
Brinzolamide is applied topically to the eye as an ophthalmic suspension. The suspension should be shaken well prior to use. If the patient is receiving more than one ophthalmic drug, the drugs should be administered at least 10 minutes apart.
For the treatment of glaucoma or ocular hypertension, the usual dosage of brinzolamide is 1 drop of a 1% suspension in the affected eye(s) 3 times daily. If further reduction in IOP is required, another topical agent that lowers IOP may be used in conjunction with brinzolamide.
No special population dosage recommendations at this time.
Known hypersensitivity to brinzolamide or any ingredient in the formulation.
Sulfonamide Sensitivity Reactions
Serious adverse events (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, other blood dyscrasias) associated with sulfonamide therapy are possible. Usual precautions associated with systemic use of sulfonamides apply. Discontinue brinzolamide therapy if serious reactions or signs or symptoms of hypersensitivity occur.
For topical use only. Not for injection or oral use.
Effect on corneal endothelium not fully evaluated.
Not studied in patients with acute angle-closure glaucoma. Acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents.
Category C. (See Users Guide.)
Brinzolamide is distributed in milk in rats following oral administration. It is not known whether brinzolamide is distributed in human milk following topical application to the eye. Discontinue nursing or the drug, taking into account the importance of the drug to the woman.
Safety and efficacy not established in children.
No overall differences in safety and efficacy relative to younger adults.
Not studied in patients with hepatic impairment; use with caution.
Not studied in patients with severe renal impairment (creatinine clearance less than 30 mL/minute). Not recommended in such patients, since brinzolamide and its metabolite are excreted mainly by the kidneys.
Common Adverse Effects
Adverse effects reported in 1% or more of patients receiving brinzolamide include blurred vision, taste abnormality (bitter, sour, or unusual taste), blepharitis, dermatitis, dry eye, foreign body sensation, headache, hyperemia, ocular discharge, ocular discomfort, ocular keratitis, ocular pain, ocular pruritus, and rhinitis.
Potential pharmacodynamic interaction. Acid-base disturbances produced by oral carbonic anhydrase inhibitors have been associated with toxicity in some patients receiving high-dose salicylates. (See Drug Interactions in the Carbonic Anhydrase Inhibitors General Statement 52:10 and Drug Interactions: Acidifying and Alkalinizing Agents, in the Salicylates General Statement 28:08.04.24.)